Dyadic International, Inc (NASDAQ:DYAI) has earned an average broker rating score of 1.00 (Strong Buy) from the one analysts that cover the stock, Zacks Investment Research reports. One equities research analyst has rated the stock with a strong buy rating.
Analysts have set a 12-month consensus price objective of $8.00 for the company and are predicting that the company will post ($0.07) EPS for the current quarter, according to Zacks. Zacks has also assigned Dyadic International an industry rank of 64 out of 256 based on the ratings given to its competitors.
A number of research firms have recently issued reports on DYAI. Noble Financial reaffirmed a “buy” rating and issued a $9.00 price objective on shares of Dyadic International in a research report on Monday, July 8th. TheStreet raised Social Reality from a “d+” rating to a “c-” rating in a research report on Wednesday, April 17th.
Shares of DYAI traded up $0.12 during mid-day trading on Thursday, reaching $5.10. The company’s stock had a trading volume of 61,230 shares, compared to its average volume of 95,682. Dyadic International has a 1-year low of $1.40 and a 1-year high of $7.30.
Dyadic International (NASDAQ:DYAI) last released its quarterly earnings data on Thursday, May 9th. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter. The firm had revenue of $0.40 million during the quarter. As a group, equities research analysts anticipate that Dyadic International will post -0.3 earnings per share for the current fiscal year.
In other news, VP Ronen Tchelet sold 10,000 shares of the stock in a transaction that occurred on Wednesday, July 10th. The stock was sold at an average price of $5.87, for a total transaction of $58,700.00. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 23.90% of the stock is currently owned by company insiders.
An institutional investor recently bought a new position in Dyadic International stock. NEXT Financial Group Inc purchased a new position in Dyadic International, Inc (NASDAQ:DYAI) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 8,000 shares of the biotechnology company’s stock, valued at approximately $50,000. Institutional investors own 0.05% of the company’s stock.
Dyadic International Company Profile
Dyadic International, Inc, a biotechnology platform company, engages in the development, production, and sale of enzymes and other proteins in the United States and the Netherlands. It utilizes its patented and proprietary C1 technology and other technologies to conduct research, development, and commercial production of human and animal vaccines, monoclonal antibodies, bi-specific antibodies, fab antibody fragments, FC-fusion proteins, biosimilars and/or biobetters, and other therapeutic enzymes and proteins.
Featured Story: The primary rules of Elliott Wave theory
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Dyadic International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dyadic International and related companies with MarketBeat.com's FREE daily email newsletter.